机构：[a]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,河北医科大学第四医院[b]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, China,[c]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,河北医科大学第四医院[d]Department of Internal Medicine, Affiliated Hospital of Hebei University, Baoding, China,河北大学附属医院[e]Department of Breast Cancer, People’s Hospital of Xingtai City, Xingtai, China,[f]Department of Breast Cancer, First Hospital of Qinhuangdao City, Qinhuangdao, China,[g]Department of Breast Cancer, Center Hospital of Cangzhou City, Cangzhou, China,[h]Department of Breast Cancer, People’s Hospital of Tangshan City, Tangshan, China,[i]Department of Breast Cancer, Affiliated Hospital of Hebei University of Engineering, Handan, China.河北大学附属医院
Palbociclib has shown satisfactory outcomes when combined with endocrine therapy (ET) in hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC). However, data in Asia are currently scarce.This retrospective study aimed to evaluate the real-world effectiveness, sensitivity, and toxicity of palbociclib plus ET in HR+/HER2- MBC in North China. We recruited patients with HR+/HER2- MBC from August 2018 to July 2020 across 7 hospitals in North China. The primary endpoint was to evaluate progression-free survival (PFS) after initial progress on palbociclib therapy. The secondary endpoints included determining predictive biomarkers of palbociclib sensitivity and toxicity of palbociclib.A total of 54 patients were analyzed in this cohort with an estimated median follow-up time of 14.3 months. Patients who received palbociclib as a first-line treatment showed significantly prolonged PFS compared with those who received palbociclib as a second-line or beyond treatment (21.8 months vs 15.9 months vs 6.8 months) (P < .001). Besides, patients with Ki67 <30% (P = .024) and PR >= 20% (P = .041) in metastatic tumors had significantly longer PFS. The Cox proportional-hazards regression analyses proved that different lines (P = .001 in multivariate analysis), Ki67 <30% (P = .035 in multivariate analysis), and PR >= 20% (P = .045 in univariate analysis) in metastatic tumors affected PFS significantly. The most common adverse events were hematologic, with 31.48% of patients having neutropenia.Palbociclib plus ET significantly prolonged PFS for patients with HR+/HER2- MBC who received first-line therapy, with manageable toxicity. The values of Ki67 and PR in metastatic tumors may be potential predictive biomarkers of palbociclib sensitivity.
第一作者机构：[a]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,
通讯作者：
通讯机构：[a]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,[b]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, China,[*1]Breast Center, The Fourth Hospital of Hebei Medical University, China, 12 Jiankang Road, Shijiazhuang City, Hebei Province, 050011, China
推荐引用方式(GB/T 7714)：
Jingping Li,Xiangmei Zhang,Chao Yang,et al.Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer[J].MEDICINE.2021,100(44):e27710.doi:10.1097/MD.0000000000027710.
APA：
Jingping Li,Xiangmei Zhang,Chao Yang,Yalei Lv,Hua Yang...&Yunjiang Liu.(2021).Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer.MEDICINE,100,(44)
MLA：
Jingping Li,et al."Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer".MEDICINE 100..44(2021):e27710
